164 related articles for article (PubMed ID: 31828091)
1. Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.
Qian Y; Pan Z; Guo Z; Ge X; Zheng G; Cao J; Huang P; Zhu X; Zhu X; Wen Q; Ge M
Biomed Res Int; 2019; 2019():1791065. PubMed ID: 31828091
[TBL] [Abstract][Full Text] [Related]
2. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
Tang J; Gui C; Qiu S; Wang M
World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
[TBL] [Abstract][Full Text] [Related]
4. Dynamin 2 Is Correlated with Recurrence and Poor Prognosis of Papillary Thyroid Cancer.
Ren N; Tian Z; Sun H; Lu X
Med Sci Monit; 2020 Aug; 26():e924590. PubMed ID: 32827429
[TBL] [Abstract][Full Text] [Related]
5. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.
Che X; Zhang G; Zhang X; Xue J
Med Sci Monit; 2018 May; 24():3540-3548. PubMed ID: 29805156
[TBL] [Abstract][Full Text] [Related]
7. A-kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients.
Zhang L; Tao H; Ke K; Ma C
J Clin Lab Anal; 2020 Oct; 34(10):e23452. PubMed ID: 32643206
[TBL] [Abstract][Full Text] [Related]
8. Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma.
Chen X; Jin J; Zheng L; Sheng Y; Sun J
J BUON; 2021; 26(1):259-265. PubMed ID: 33721460
[TBL] [Abstract][Full Text] [Related]
9. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
10. Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.
Xu W; Wang L; An Y; Ye J
Med Sci Monit; 2019 May; 25():3762-3770. PubMed ID: 31107859
[TBL] [Abstract][Full Text] [Related]
11. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma.
Xing Y; Luo DY; Long MY; Zeng SL; Li HH
World J Surg Oncol; 2014 Feb; 12():29. PubMed ID: 24485040
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of STIP1 in papillary thyroid carcinoma.
Yuan MH; Zhou RS; She B; Xu HF; Wang JY; Wei LX
Tumour Biol; 2014 Mar; 35(3):2391-5. PubMed ID: 24163084
[TBL] [Abstract][Full Text] [Related]
13. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 "SLC34A2" in Papillary Thyroid Carcinoma: An Immunohistochemical Study.
Hakim SA; Abd El Atti RM; Faheim RM; Abou Gabal HH
Anal Cell Pathol (Amst); 2021; 2021():3198555. PubMed ID: 34336552
[TBL] [Abstract][Full Text] [Related]
15. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
16. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
Ahn HY; Song RY; Ahn HS; Kim HS
Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
18. Level V Metastasis, a Novel Predicative Factor for Recurrence in N1b Papillary Thyroid Carcinoma.
Wu Y; Li J; Wu X; Dai L
Curr Pharm Des; 2018; 24(5):559-563. PubMed ID: 28990528
[TBL] [Abstract][Full Text] [Related]
19. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
20. Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer.
Wen S; Luo Y; Wu W; Zhang T; Yang Y; Ji Q; Wu Y; Shi R; Ma B; Xu M; Qu N
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1579-1589. PubMed ID: 34693452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
